After the UK medicines regulator yesterday approved Merck’s Covid pill for use on recently infected, vulnerable patients, Pfizer announced its own successful treatment, Paxlovid. Pfizer’s pill was shown to reduce the risk of hospitalisation and death in Covid patients by up to 89 per cent compared with a placebo.
The drug has proved so effective that enrolment in the trial has been stopped and Pfizer says it plans to apply to the US regulator for emergency use ‘as soon as possible’. The pill is most effective when treatment starts as soon as a patient becomes aware they are infected with or have been exposed to the virus. It’s taken with a pre-existing HIV drug — ritonavir — which helps it stay in the body for longer. Pfizer scientists say it works by blocking the activity of an enzyme that the virus needs in order to replicate itself.
In the period that ten people died after receiving the placebo there were no deaths in the treatment group.
Get Britain's best politics newsletters
Register to get The Spectator's insight and opinion straight to your inbox. You can then read two free articles each week.
Already a subscriber? Log in
Comments
Join the debate for just £1 a month
Be part of the conversation with other Spectator readers by getting your first three months for £3.
UNLOCK ACCESS Just £1 a monthAlready a subscriber? Log in